drugset
drugset / Trial / NCT01091272

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

NCT01091272 ↗

Phase 1 Completed 28 enrolled Pfizer
RandomizedCrossoverDouble-blind

Summary

The purpose of the study is to evaluate the safety and tolerability of PF-04995274 after administration of a single dose to healthy volunteers, and to evaluate the plasma drug concentrations after single dose in healthy volunteers.

Timeline

Start
2010-04
Primary completion
2010-08
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04995274 Small molecule 0.15 mg Oral
Subject PF-04995274 Small molecule 0.5 mg Oral
Subject PF-04995274 Small molecule 1.5 mg Oral
Subject PF-04995274 Small molecule 5 mg Oral
Subject PF-04995274 Small molecule 15 mg Oral
Subject PF-04995274 Small molecule 50 mg Oral
Subject PF-04995274 Small molecule 120 mg Oral
Subject PF-04995274 Small molecule 210 mg Oral

Indications

No indication recorded.